142 Evaluation of Direct Oral Anticoagulant Eligibility and Prescribing for Primary Venous Thromboembolism Prevention in High-Risk Ambulatory Patients with Cancer

Introduction: Venous thromboembolism (VTE) significantly impacts morbidity and mortality in patients with active cancer. Venous thromboembolism in patients with cancer can disrupt or delay treatment, potentially worsening outcomes. Long-term effects of VTE, such as post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension, can diminish quality of life and impose substantial financial burdens. Historically, thromboprophylaxis was limited to parenteral anticoagulants which presents as a challenge for patient self-administration in the ambulatory setting.